<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35333675</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anti-phospholipase A2 receptor antibodies directly induced podocyte damage <i>in vitro</i>.</ArticleTitle>
        <Pagination>
          <StartPage>304</StartPage>
          <EndPage>313</EndPage>
          <MedlinePgn>304-313</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2039705</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The pathogenesis of primary membranous nephropathy (MN) involves the antibodies against antigens on the cell surface of podocytes, with the majority of M-type phospholipase A2 receptor (PLA2R), and a profound podocyte dysfunction. The effects of anti-PLA2R antibodies directly to the podocytes remain unclear.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Anti-PLA2R antibodies from patients with PLA2R-associated MN were affinity-purified using a column coupled with recombinant human PLA2R protein. Their effects on conditionally immortalized human podocytes were assessed by apoptosis assays, cellular calcium detection, wound healing assay, and immunofluorescent staining. Proteomics analysis was performed by LC-MS/MS and on PANTHER database.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The stimulation by anti-PLA2R antibodies could induce early-stage apoptosis of podocytes (MFI of Annexin <i>V</i> = 104.3 ± 19.2 vs. 36.7 ± 7.6, <i>p</i> = 0.004). The increase of calcium concentration in podocytes (MFI = 3309.3 ± 363.6 vs. 1776.3 ± 212.7, <i>p</i> = 0.015) might attribute to the endoplasmic reticulum calcium efflux. The expression of calcium/calmodulin-dependent protein kinase IV (CaMK4) was also increased (MFI = 134.4 ± 9.8 vs. 105.3 ± 10.1, <i>p</i> = 0.011). Proteomics results suggested that anti-PLA2R antibody treatment led to damage on cellular structure, and produced functional disorders on protein binding, actin filament binding, and microtubule motor activity. The staining of F-actin on foot process was reduced (MFI = 27.3 ± 2.8 vs. 47.5 ± 1.0, <i>p</i> = 0.001) and the motility and adherence capacity of podocytes were reduced (number of migrated cells = 44.7 ± 3.1 vs. 53.3 ± 4.9, <i>p</i> = 0.001) after incubation with anti-PLA2R antibodies.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These data indicate that anti-PLA2R antibodies may directly induce podocyte damage independent of the complement system, which expands the mechanism of anti-PLA2R antibodies on MN.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yanfen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology and Renal Division, Peking University First Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Juntao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Kintor Pharmaceutical Limited, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Miao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology and Renal Division, Peking University First Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology and Renal Division, Peking University First Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Ming-Hui</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Peking-Tsinghua Center for Life Sciences, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054507">Receptors, Phospholipase A2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015433" MajorTopicYN="Y">Glomerulonephritis, Membranous</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050199" MajorTopicYN="Y">Podocytes</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054507" MajorTopicYN="N">Receptors, Phospholipase A2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-PLA2R antibody</Keyword>
        <Keyword MajorTopicYN="N">actin</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">podocyte</Keyword>
        <Keyword MajorTopicYN="N">protein binding</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>17</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35333675</ArticleId>
        <ArticleId IdType="pmc">PMC8959519</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2039705</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Francis JM, Beck LH, Salant DJ.. 
Membranous nephropathy: a journey from bench to bedside. Am J Kidney Dis. 2016;68(1):138–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4921260</ArticleId>
            <ArticleId IdType="pubmed">27085376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck LH, Bonegio RGB, Lambeau G, et al. . 
M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2762083</ArticleId>
            <ArticleId IdType="pubmed">19571279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoxha E, Thiele I, Zahner G, et al. . 
Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357–1366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4033365</ArticleId>
            <ArticleId IdType="pubmed">24610926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoxha E, Harendza S, Pinnschmidt H, et al. . 
M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(11):1883–1890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4220763</ArticleId>
            <ArticleId IdType="pubmed">25267554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggenenti P, Debiec H, Ruggiero B, et al. . 
Anti-Phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. JASN. 2015;26(10):2545–2558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4587688</ArticleId>
            <ArticleId IdType="pubmed">25804280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haddad G, et al. . 
Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1 associated membranous nephropathy. J. Clin. Invest. 2020;131:e140453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7919733</ArticleId>
            <ArticleId IdType="pubmed">33351779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sukocheva O, Menschikowski M, Hagelgans A, et al. . 
Current insights into functions of phospholipase A2 receptor in normal and cancer cells: more questions than answers. Semin Cancer Biol. 2019;56:116–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29104026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Škoberne A, Behnert A, Teng B, et al. . 
Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen. Eur J Clin Invest. 2014;44(8):753–765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24942189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akilesh S, Huber TB, Wu H, et al. . 
Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci U S A. 2008;105(3):967–972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2242706</ArticleId>
            <ArticleId IdType="pubmed">18198272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olaru F, Luo W, Suleiman H, et al. . 
Neonatal Fc receptor promotes immune complex-mediated glomerular disease. J Am Soc Nephrol. 2014;25(5):918–925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4005300</ArticleId>
            <ArticleId IdType="pubmed">24357670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ichinose K, Ushigusa T, Nishino A, et al. . 
Lupus nephritis IgG induction of calcium/calmodulin-dependent protein kinase IV expression in podocytes and alteration of their function. Arthritis Rheumatol. 2016;68(4):944–952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6103450</ArticleId>
            <ArticleId IdType="pubmed">26636664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kavran JM, Leahy DJ.. 
Coupling antibody to cyanogen bromide-activated sepharose. Methods Enzymol. 2014;541:27–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4337859</ArticleId>
            <ArticleId IdType="pubmed">24674060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Liu G, Zhang Y-M, et al. . 
Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014;12(1):81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4064821</ArticleId>
            <ArticleId IdType="pubmed">24884842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemrow SM, Anderson KA, Joseph JD, et al. . 
Catalytic activity is required for calcium/calmodulin-dependent protein kinase IV to enter the nucleus. J Biol Chem. 2004;279(12):11664–11671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14701808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotera I, Sekimoto T, Miyamoto Y, et al. . 
Importin alpha transports CaMKIV to the nucleus without utilizing importin beta. Embo J. 2005;24(5):942–951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC554133</ArticleId>
            <ArticleId IdType="pubmed">15719015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber TB, Hartleben B, Winkelmann K, et al. . 
Loss of podocyte aPKCλ/ι causes polarity defects and nephrotic syndrome. J Am Soc Nephrol. 2009;20(4):798–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663834</ArticleId>
            <ArticleId IdType="pubmed">19279126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartleben B, Widmeier E, Suhm M, et al. . 
aPKCλ/ι and aPKCζ contribute to podocyte differentiation and glomerular maturation. J Am Soc Nephrol. 2013;24(2):253–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3559483</ArticleId>
            <ArticleId IdType="pubmed">23334392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilatovskaya DV, Blass G, Palygin O, et al. . 
A NOX4/TRPC6 pathway in podocyte calcium regulation and renal damage in diabetic kidney disease. J Am Soc Nephrol. 2018;29(7):1917–1927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6050934</ArticleId>
            <ArticleId IdType="pubmed">29793963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinton P, Giorgi C, Siviero R, et al. . 
Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene. 2008;27(50):6407–6418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2844952</ArticleId>
            <ArticleId IdType="pubmed">18955969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orrenius S, Zhivotovsky B, Nicotera P.. 
Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4(7):552–565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12838338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sj P, C L.Ym C.. 
Endoplasmic reticulum calcium homeostasis in kidney disease: pathogenesis and therapeutic targets. Am. J. Pathol. 2021;191:256–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7863132</ArticleId>
            <ArticleId IdType="pubmed">33245915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Doné SC, Khoshnoodi J, et al. . 
Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet. 2001;10(23):2637–2644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11726550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schell C, Huber TB.. 
The evolving complexity of the podocyte cytoskeleton. J Am Soc Nephrol. 2017;28(11):3166–3174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5661293</ArticleId>
            <ArticleId IdType="pubmed">28864466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sever S, Schiffer M.. 
Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases. Kidney Int. 2018;93(6):1298–1307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5967993</ArticleId>
            <ArticleId IdType="pubmed">29678354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suleiman HY, Roth R, Jain S, et al. . 
Injury-induced actin cytoskeleton reorganization in podocytes revealed by super-resolution microscopy. JCI Insight. 2017;2(16): e94137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5621879</ArticleId>
            <ArticleId IdType="pubmed">28814668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mella A, Deambrosis I, Mingozzi S, et al. . 
Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy. Sci Rep. 2020;10(1):16362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7530666</ArticleId>
            <ArticleId IdType="pubmed">33004982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shankland SJ.
The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69(12):2131–2147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16688120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nangaku M, Shankland SJ, Couser WG.. 
Cellular response to injury in membranous nephropathy. J Am Soc Nephrol. 2005;16(5):1195–1204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15800119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan YB, et al. . 
sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor. Sci. Rep. 2014;4:6660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4205892</ArticleId>
            <ArticleId IdType="pubmed">25335547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vindrieux D, Augert A, Girard CA, et al. . 
PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res. 2013;73(20):6334–6345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24008317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griveau A, Devailly G, Eberst L, et al. . 
The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action. Oncogene. 2016;35(38):5033–5042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27041564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Augert A, Vindrieux D, Girard CA, et al. . 
PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med. 2013;65:969–977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23994771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernard D, Vindrieux D.. 
PLA2R1: expression and function in cancer. Biochim Biophys Acta. 2014;1846(1):40–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24667060</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
